查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995236

藥物釋放型支架市場：按類型、藥物、應用、最終用戶和分銷管道分類－2026-2032年全球市場預測

Drug Eluting Stent Market by Type, Drug, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，藥物釋放型支架市場價值將達到 63.5 億美元，到 2026 年將成長至 67.5 億美元，到 2032 年將達到 112.2 億美元，複合年成長率為 8.46%。

主要市場統計數據
基準年 2025 63.5億美元
預計年份：2026年 67.5億美元
預測年份 2032 112.2億美元
複合年成長率 (%) 8.46%

全面介紹藥物釋放型支架的臨床意義、設備發展歷程、監管途徑以及影響其應用的策略挑戰。

藥物釋放型支架已成為介入性心臟病學和血管內治療中至關重要的治療工具，並已納入多種動脈粥狀硬化性疾病的現代治療方案。過去20年間，這些裝置從第一代設計發展成為結合了抗增殖藥物遞送、精密支架和聚合物技術的先進平台。這一發展得益於生物相容性、藥物遞送和臨床療效的不斷改進，以及透過隨機對照試驗和真實世界臨床註冊研究持續累積的證據。

對藥物釋放型支架領域中改變患者預後和市場動態的變革性技術、臨床和商業性變化進行分析。

藥物釋放型支架領域正經歷技術、臨床和市場因素的整合變革，這些因素共同作用，帶來革命性的改變。材料科學的進步使得支架支柱設計更加纖細、生物相容性塗層更加優異成為可能，而藥物製劑的創新則進一步提升了這些硬體性能，旨在最佳化局部抗增殖效果，同時最大限度地減少全身暴露。因此，器械的差異化越來越依賴一些細微的性能特徵，例如內皮細胞修復情況、在複雜解剖結構中的遞送以及與輔助成像和生理評估工具的兼容性。

對 2025 年美國關稅措施及其對供應鏈、籌資策略和藥物釋放型支架取得的影響進行詳細評估。

美國2025年實施的關稅措施可能會對整個全球醫療設備供應鏈產生連鎖反應，影響採購、庫存管理和籌資策略。最初的影響將最為顯著，尤其是在生產投入品和成品跨境運輸時，這些環節將受到關稅上漲的影響，迫使採購機構重新評估供應商所在地，並在成本、交貨前置作業時間和供應商可靠性之間權衡取捨。為此，一些醫療機構可能會擴大供應商範圍，優先選擇具有本地生產能力的供應商，或透過合約談判來降低短期價格波動帶來的影響。

細分市場洞察揭示了類型、藥物、適應症、最終用戶和分銷方面的細微差異如何影響臨床選擇、採購優先事項和商業化。

藥物釋放型支架領域的細分市場差異會影響臨床決策和商業策略，因此，全面了解支架類型、藥物、應用、最終用戶和分銷管道對於掌握市場趨勢至關重要。就器械類型而言，市場區分聚合物塗層系統和無聚合物平台。在聚合物塗層產品中，進一步區分了旨在隨時間推移被吸收的生物可分解聚合物塗層設計和能夠長期保持塗層特性的耐用聚合物塗層結構。這些差異會影響癒合的生物機制、延遲不利事件的發生以及向臨床醫生傳達的關於長期血管通暢性的訊息。

決定藥物釋放型支架在不同醫療保健系統和經濟區域臨床引入、購買行為和報銷方式的區域趨勢。

區域趨勢對藥物釋放型支架的採用、報銷和整合到治療方案中具有顯著影響，了解這些差異對於跨國策略和區域性商業化計畫至關重要。在美洲，公共和私人支付方的報銷框架各不相同，採購方在評估新型支架平台時通常優先考慮臨床數據和手術經濟性。採購週期可能集中在醫院網路內，也可能分散在各個醫療機構，這種多樣性會影響製造商如何展示產品價值以及如何談判供應合約。

在不斷變化的臨床、監管和支付環境背景下，開發和商業化藥物釋放型支架的公司的競爭格局和策略重點

藥物釋放型支架領域的企業競爭格局取決於產品創新、實證醫學證據的累積以及展現永續臨床和經濟價值的能力。成熟的製造商通常憑藉廣泛的產品系列、全球監管核准和豐富的上市後數據來保持領先地位，而高度專業化的創新者則致力於透過差異化的設計特徵和特定適應症來引領臨床應用。那些能夠將強大的臨床項目與有針對性的真實世界數據（REW）收集相結合的企業，往往對採購決策產生更大的影響，因為它們可以同時解決療效和長期安全性問題。

為領導者提供可操作的建議，以加速藥物釋放型支架領域的創新、最佳化採購並改善臨床和商業性成果。

產業領導者可以採取實際措施，加速創新、確保供應連續性、強化商業性地位，同時改善病患療效。首先，優先制定清晰的證據藍圖，結合隨機臨床試驗和可操作的註冊研究，既能滿足監管要求，又能解決臨床醫生和支付方的實際顧慮。其次，投資區域製造能力並實現供應鏈多元化，包括關鍵原料的檢驗二級供應商，可以降低貿易中斷帶來的風險，並有助於與大規模醫療系統進行更可預測的採購談判。

本文總結了藥物釋放型支架研究中使用的調查方法，包括臨床文獻的整合、與專家和相關人員的對話、資料檢驗和分析技術。

本報告的研究結果是基於多方面的研究途徑，該方法整合了臨床文獻、專家和相關人員的見解以及檢驗的資料來源。分析過程首先對同行評審的臨床研究、指南文件和監管申報文件進行系統性回顧，以確定支架技術的臨床表現標準。除此二手資料分析外，還與介入性心臟病專家、血管專家、採購經理和分銷合作夥伴進行了結構化訪談和諮詢，以了解他們對醫療設備選擇、手術流程和供應鏈限制的實際觀點。

摘要重點闡述了策略重點、創新需求以及為改善患者療效和產業韌性而進行的合作努力。

總而言之，由於材料科學的進步、臨床實踐的演進以及商業性預期的變化，藥物釋放型支架領域正處於轉折點。持續的差異化取決於器械平台能否在適應現代介入醫學手術實際情況的同時，展現出具有臨床意義的改進。同時，貿易政策的變化以及對彈性供應鏈的需求等外部壓力正在影響採購行為和產品供應，這既給製造商和醫療保健系統帶來了挑戰，也帶來了戰略機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：藥物釋放型支架市場：依類型分類

  • 聚合物塗層
    • 可生物分解聚合物塗層
    • 耐用聚合物塗層
  • 不含聚合物

第9章：按藥物類型分類的藥物釋放型支架市場

  • Biolims溶解型
  • Everolimus洗脫型
  • 紫杉醇洗脫型
  • Sirolimus洗脫型

第10章：藥物釋放型支架市場：依應用領域分類

  • 冠狀動脈疾病
  • 周邊血管疾病

第11章：藥物釋放型支架市場：依最終用戶分類

  • 門診手術中心
  • 醫院

第12章：藥物釋放型支架市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：藥物釋放型支架市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：藥物釋放型支架市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：藥物釋放型支架市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國藥物釋放型支架市場

第17章：中國藥物釋放型支架市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Biosensors International Group, Ltd.
  • BIOTRONIK AG
  • Boston Scientific Corporation
  • Elixir Medical Corp
  • Johnson & Johnson
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medtronic plc
  • Meril Life Sciences Private Limited
  • MicroPort Scientific Corporation
  • Terumo Corporation
Product Code: MRR-807A20B5CCC6

The Drug Eluting Stent Market was valued at USD 6.35 billion in 2025 and is projected to grow to USD 6.75 billion in 2026, with a CAGR of 8.46%, reaching USD 11.22 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.35 billion
Estimated Year [2026] USD 6.75 billion
Forecast Year [2032] USD 11.22 billion
CAGR (%) 8.46%

Comprehensive introduction outlining clinical relevance, device evolution, regulatory pathways, and strategic imperatives shaping adoption of drug eluting stents

Drug eluting stents have become a pivotal therapeutic intervention in interventional cardiology and vascular medicine, embedding themselves within modern treatment pathways for a range of atherosclerotic conditions. Over the past two decades, these devices have evolved from first-generation designs into sophisticated platforms that balance antiproliferative drug delivery with refined scaffold and polymer technology. This evolution has been driven by iterative improvements in biocompatibility, deliverability, and clinical outcomes, and by a continuous cycle of evidence generation across randomized trials and real-world registries.

Clinicians and procurement leaders now must navigate a landscape in which device choice influences procedural success, long-term vessel patency, and downstream resource utilization. As such, understanding the interplay of device design, drug kinetics, polymer behavior, and clinical indication is central to optimizing patient care and institutional performance. Simultaneously, regulatory scrutiny and payer requirements have shifted priorities toward demonstrable safety and long-term effectiveness, prompting manufacturers to emphasize post-market data and differentiated clinical claims. In this context, the present summary frames the strategic, clinical, and commercial considerations that underpin decision making for stakeholders across hospitals, ambulatory centers, and distribution channels.

Analysis of transformative technological, clinical, and commercial shifts redefining patient outcomes and market dynamics within the drug eluting stent landscape

The drug eluting stent landscape is being reshaped by converging technological, clinical, and market forces that together constitute transformative change. Advances in materials science have enabled thinner strut designs and more biocompatible coatings, and these hardware refinements are complemented by innovations in drug formulation that aim to optimize local antiproliferative effects while minimizing systemic exposure. As a result, device differentiation increasingly rests on nuanced performance characteristics such as endothelial healing profiles, deliverability in complex anatomies, and compatibility with adjunctive imaging and physiologic assessment tools.

Concurrently, clinical practice is evolving: operators are integrating intravascular imaging and physiologic guidance into routine workflows, which alters device selection criteria and procedural approaches. This trend toward precision deployment is creating opportunities for stent platforms that demonstrate predictable and reproducible behavior under image-guided techniques. From a commercial perspective, healthcare systems are emphasizing total cost of care and long-term outcomes, which elevates the importance of robust post-market evidence and value-based contracting. Additionally, the competitive dynamic is intensifying as specialized innovators introduce niche designs while established manufacturers pursue portfolio breadth and lifecycle management. Regulatory expectations have likewise become more rigorous, with stronger emphasis on longer-term safety data and real-world performance, prompting manufacturers to invest in longitudinal registries and adaptive study designs. Taken together, these shifts are redefining how clinical value is demonstrated, how products are procured, and how companies prioritize R&D and market access activities.

In-depth assessment of United States tariff actions in 2025 and their effects on supply chains, procurement strategies, and access to drug eluting stents

The imposition of United States tariff measures in 2025 has the potential to reverberate across global supply chains for medical devices, creating tangible implications for procurement, inventory management, and sourcing strategies. Early effects are most pronounced where manufacturing inputs or finished devices cross borders subject to increased duties, prompting purchasing organizations to reassess supplier footprints and to evaluate the tradeoffs between cost, lead time, and supplier reliability. In response, some health systems may broaden their supplier base, prioritize vendors with local manufacturing capabilities, or negotiate contractual protections to mitigate short-term price volatility.

At the operational level, device manufacturers and distributors are likely to revisit logistics strategies, increasing the emphasis on alternative routing, regional warehousing, and multi-sourcing to preserve continuity of supply. These adjustments can lengthen planning cycles and raise working capital requirements, particularly for high-value implantable devices. Moreover, procurement teams may adjust tender evaluation frameworks to incorporate duty-related cost differentials and supply chain resilience metrics, thereby altering competitive positioning for suppliers whose cost base is sensitive to tariff exposure.

Clinically, stakeholders will need to ensure that any shifts in sourcing do not compromise device quality or clinical outcomes. This necessitates rigorous supplier qualification, accelerated validation of alternative manufacturing sites, and careful management of device transition protocols at the hospital and ambulatory center level. From an innovation standpoint, tariffs can increase incentives for local production and technology transfer, potentially accelerating investments in domestic manufacturing capacity and in-region regulatory submissions. Ultimately, while tariffs may create near-term disruption and cost pressure, they also catalyze strategic shifts that influence how manufacturers and health systems think about resilience, supplier relationships, and geographic diversification of manufacturing.

Segmentation insights revealing how type, drug, application, end user, and distribution nuances drive clinical choice, procurement priorities, and commercialization

Segment-level differentiation in the drug eluting stent space drives both clinical decision making and commercial strategy, and an integrated view of type, drug, application, end user, and distribution channel is essential to appreciate adoption dynamics. Regarding device type, the market distinguishes between polymer coated systems and polymer free platforms; within polymer coated offerings, there is a further split between biodegradable polymer coated designs that aim to resorb over time and durable polymer coated constructs that retain their coating profile long term. These distinctions influence healing biology, late adverse event profiles, and messaging for clinicians focused on long-term vessel patency.

Drug selection represents another axis of differentiation, with devices eluting agents such as biolimus, everolimus, paclitaxel, and sirolimus. Each drug differs in pharmacologic potency, tissue retention characteristics, and historical evidence base, which affects device positioning for specific lesion types and patient risk cohorts. Application context matters as well: the clinical needs and performance expectations for coronary artery disease differ from those for peripheral vascular disease, and device attributes are weighed differently when operators manage challenging peripheral anatomies or seek durable improvement in limb perfusion.

End users also frame purchasing and utilization patterns. Hospitals typically drive higher procedural volumes and manage complex cases requiring a broad set of device options and rapid supply availability, whereas ambulatory surgical centers focus on efficiency, predictable outcomes, and devices that facilitate short-stay workflows. Finally, distribution channels shape access and procurement pathways: hospital pharmacies, online pharmacy platforms, and retail pharmacies each present distinct routing, inventory, and reimbursement considerations that affect how devices reach point-of-care. Taken together, these segmentation dimensions inform product development priorities, evidence generation plans, and commercialization strategies, and they underscore the need for tailored value propositions that resonate with clinicians, supply chain managers, and payers across diverse care settings.

Regional dynamics that determine clinical adoption, purchasing behavior, and reimbursement approaches for drug eluting stents across diverse healthcare systems and economies

Regional dynamics materially influence how drug eluting stents are adopted, reimbursed, and integrated into care pathways, and understanding these differences is critical for multinational strategy and for localized commercialization plans. In the Americas, reimbursement frameworks vary across public and private payers, and purchasers often emphasize comparative clinical data and procedural economics when evaluating new stent platforms. Procurement cycles can be centralized within hospital networks or decentralized across individual institutions, and this variability shapes how manufacturers present value and negotiate supply agreements.

Across Europe, Middle East & Africa the landscape is heterogeneous, with regulatory processes, reimbursement timelines, and clinical practice patterns differing significantly between advanced European markets and emerging economies. In many jurisdictions within this region, health technology assessment outcomes and national procurement programs play an outsized role in determining market access, which requires manufacturers to align clinical evidence packages with payer expectations and to consider regional partnerships to expedite market entry.

In Asia-Pacific, growth in interventional procedures is accompanied by diverse regulatory pathways and varying levels of local manufacturing capability. Some markets prioritize cost-effective devices and demonstrate rapid adoption of technologies that deliver demonstrable improvements in throughput and outcomes, whereas others emphasize domestic industry development and localization. Across all regions, the interplay of clinical training, availability of intravascular imaging, and the structure of hospital reimbursement shapes device selection and the pace at which new platforms gain traction. Therefore, a regionally nuanced approach to evidence generation, pricing, and stakeholder engagement is essential to maximize clinical uptake and to address local system constraints.

Competitive profiles and strategic priorities for companies developing and commercializing drug eluting stents amid clinical, regulatory, and payer shifts

Competitive dynamics among companies engaged with drug eluting stents are defined by product innovation, evidence generation, and the ability to demonstrate sustainable clinical and economic value. Established manufacturers typically leverage broad portfolios, global regulatory clearances, and extensive post-market datasets to maintain leadership, while specialized innovators focus on differentiated design features or niche indications to create pathways for clinical adoption. Firms that balance robust clinical programs with targeted real-world evidence collection tend to influence purchasing decisions more effectively because they can address both efficacy and longer-term safety concerns.

Partnerships and strategic alliances are increasingly important as companies seek to combine complementary capabilities, such as device engineering, drug formulation expertise, and regional market access. Supply chain resilience has become a core strategic priority, prompting manufacturers to diversify production footprints, validate multiple suppliers for critical components, and invest in quality systems that support rapid scaling. Commercially, companies that offer comprehensive training, implementation support, and data-driven value propositions find greater receptivity among hospital systems focused on procedural consistency and outcome optimization. In sum, market leaders and challengers alike must align R&D investments, evidence strategies, and supply chain planning with the shifting expectations of clinicians, health systems, and payers to sustain competitive advantage.

Practical recommendations for leaders to accelerate innovation, optimize procurement, and improve clinical and commercial outcomes in the drug eluting stent space

Industry leaders can take concrete actions to accelerate innovation, safeguard supply continuity, and strengthen commercial positioning while improving patient outcomes. First, prioritizing a clear evidence roadmap that couples randomized clinical studies with pragmatic registries will address both regulatory requirements and the practical concerns of clinicians and payers. Second, investing in supply chain diversification, including regional manufacturing capabilities and validated secondary suppliers for critical inputs, will reduce vulnerability to trade disruptions and support more predictable procurement conversations with large health systems.

Third, aligning product design with the realities of image-guided intervention and emerging care pathways will enhance clinical differentiation; platforms that demonstrably facilitate intravascular imaging, predictable deployment, and consistent healing profiles will be more attractive in settings that demand precision. Fourth, manufacturers should expand commercial models to include value-based contracting pilots and outcome-linked agreements where feasible, enabling closer alignment with health system priorities. Finally, advancing clinician education and deployment support, including procedural training and data-sharing initiatives, will improve uptake and optimize real-world performance. By executing these measures in an integrated manner, industry leaders can balance immediate operational challenges with longer term innovation goals.

Methodology summarizing clinical literature synthesis, expert stakeholder engagement, data validation, and analytical techniques used in drug eluting stent studies

This report's findings are rooted in a multi-method research approach that synthesizes clinical literature, expert stakeholder insights, and validated data sources. The analytical process began with systematic reviews of peer-reviewed clinical studies, guideline documents, and regulatory submissions to establish the clinical performance benchmarks for stent technologies. These secondary-source analyses were complemented by structured interviews and consultations with interventional cardiologists, vascular specialists, procurement leaders, and distribution partners to capture frontline perspectives on device selection, procedural workflow, and supply chain constraints.

Primary data collection included targeted qualitative interviews and the review of anonymized procedural registries to validate patterns observed in the literature. Data triangulation and validation were performed through cross-referencing clinical outcomes with stakeholder feedback and operational considerations, and methodological transparency was maintained by documenting inclusion criteria, interview protocols, and data-cleaning processes. Wherever applicable, results were contextualized against regulatory frameworks and reimbursement practices to ensure that the insights provided reflect both clinical realities and commercial imperatives.

Concluding synthesis stressing strategic priorities, innovation imperatives, and coordinated actions to improve patient outcomes and sector resilience

In synthesis, the drug eluting stent domain is at an inflection point driven by material science advances, evolving clinical practice, and shifting commercial expectations. Continued differentiation will depend on the ability of device platforms to demonstrate clinically meaningful improvements while fitting into the procedural realities of modern interventional practice. At the same time, external pressures such as trade policy changes and the demand for resilient supply chains will influence procurement behavior and product availability, creating both challenges and strategic opportunities for manufacturers and health systems.

To navigate this environment, stakeholders must adopt a coordinated approach that marries robust evidence generation with operational resilience and thoughtful commercialization. Clinical leaders should continue to embrace image-guided and physiology-driven practices, procurement teams must incorporate supply chain risk into purchasing frameworks, and manufacturers need to pursue focused innovation supported by compelling real-world data. This holistic orientation will help ensure that advances in device technology translate into sustained improvements in patient care and durable value for healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Eluting Stent Market, by Type

  • 8.1. Polymer Coated
    • 8.1.1. Biodegradable Polymer Coated
    • 8.1.2. Durable Polymer Coated
  • 8.2. Polymer Free

9. Drug Eluting Stent Market, by Drug

  • 9.1. Biolimus Eluting
  • 9.2. Everolimus Eluting
  • 9.3. Paclitaxel Eluting
  • 9.4. Sirolimus Eluting

10. Drug Eluting Stent Market, by Application

  • 10.1. Coronary Artery Disease
  • 10.2. Peripheral Vascular Disease

11. Drug Eluting Stent Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals

12. Drug Eluting Stent Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Drug Eluting Stent Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drug Eluting Stent Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug Eluting Stent Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Drug Eluting Stent Market

17. China Drug Eluting Stent Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Biosensors International Group, Ltd.
  • 18.7. BIOTRONIK AG
  • 18.8. Boston Scientific Corporation
  • 18.9. Elixir Medical Corp
  • 18.10. Johnson & Johnson
  • 18.11. Lepu Medical Technology (Beijing) Co., Ltd.
  • 18.12. Medtronic plc
  • 18.13. Meril Life Sciences Private Limited
  • 18.14. MicroPort Scientific Corporation
  • 18.15. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG ELUTING STENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUG ELUTING STENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY BIOLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. GCC DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 121. GCC DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 122. GCC DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. GCC DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. GCC DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. G7 DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 142. G7 DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 143. G7 DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. G7 DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. G7 DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. NATO DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 149. NATO DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 150. NATO DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. NATO DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. NATO DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA DRUG ELUTING STENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA DRUG ELUTING STENT MARKET SIZE, BY POLYMER COATED, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA DRUG ELUTING STENT MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA DRUG ELUTING STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA DRUG ELUTING STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA DRUG ELUTING STENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)